High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease by Balfe, Peter et al.
 
 
University of Birmingham
High resolution sequencing of hepatitis C virus
reveals limited intra-hepatic compartmentalization
in end stage liver disease
Balfe, Peter; McKeating, Jane; Hedegaard, Ditte; Reynolds, Gary; Hu, Ke; Wilhelm, Annika;
Kelly, Deidre
DOI:
10.1016/j.jhep.2016.07.048
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Balfe, P, McKeating, J, Hedegaard, D, Reynolds, G, Hu, K, Wilhelm, A & Kelly, D 2017, 'High resolution
sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease',
Journal of Hepatology, vol. 66, pp. 28-38. https://doi.org/10.1016/j.jhep.2016.07.048
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Accepted Manuscript
High resolution sequencing of hepatitis C virus reveals limited intra-hepatic
compartmentalization in end stage liver disease
Ditte L. Hedegaard, Damien C. Tully, Ian A. Rowe, Gary M. Reynolds, David
J. Bean, Ke Hu, Christopher Davis, Annika Wilhelm, Colin B. Ogilvie, Karen
A. Power, Alexander W. Tarr, Deirdre Kelly, Todd M. Allen, Peter Balfe, Jane
A. McKeating
PII: S0168-8278(16)30424-X
DOI: http://dx.doi.org/10.1016/j.jhep.2016.07.048
Reference: JHEPAT 6230
To appear in: Journal of Hepatology
Received Date: 13 May 2016
Revised Date: 22 July 2016
Accepted Date: 29 July 2016
Please cite this article as: Hedegaard, D.L., Tully, D.C., Rowe, I.A., Reynolds, G.M., Bean, D.J., Hu, K., Davis, C.,
Wilhelm, A., Ogilvie, C.B., Power, K.A., Tarr, A.W., Kelly, D., Allen, T.M., Balfe, P., McKeating, J.A., High
resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver
disease, Journal of Hepatology (2016), doi: http://dx.doi.org/10.1016/j.jhep.2016.07.048
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
 
High resolution sequencing of hepatitis C virus reveals limited  
intra-hepatic compartmentalization in end stage liver disease. 
 
Ditte L. Hedegaard
1*
, Damien C. Tully
2*
, Ian A. Rowe
1,¶
, Gary M. Reynolds
3
, David J. Bean
2
, Ke Hu
1
, Christopher 
Davis
1
, Annika Wilhelm
3
, Colin B. Ogilvie
2
, Karen A. Power
2
, Alexander W. Tarr
4
, Deirdre Kelly
5
, 
Todd M. Allen
2
, Peter Balfe
1,†,#
 and Jane A. McKeating
1,3,6,†
 
1) Centre for Human Virology, University of Birmingham, Birmingham, UK. 
2) Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA. 
3) NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, UK 
4) School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, 
UK 
5) Liver Unit, Birmingham Childrens’ Hospital, Birmingham, UK 
6) Institute for Advanced Study, Technische Universität München, Lichtenbergstrasse 2a, D-85748 Garching, 
Germany. 
 
* Shared first authorship 
† Shared senior Authorship 
¶ Current Address: Leeds Institute for Data Analytics, University of Leeds, UK 
# - Corresponding author: p.balfe@bham.ac.uk, tel: (44)121 414 8174, fax: (44)121 414 3599 
 
 
Keywords: Hepatitis C; ESLD; Evolution; Compartmentalization; Innate immunity 
Authors' contributions: DLH, DCT, IAH, GMR, DJB, KH, CD and PB performed the work described here. AW, 
CBO, KAP, AT and DK provided key expertise and reagents. DLH, DK, TMA, JAM and PB designed the study. 
DLH, DCT, JAM and PB wrote the manuscript. 
Conflict of interest: The authors who have taken part in this study declare that they do not have anything to 
disclose regarding funding or conflict of interest with respect to this manuscript. 
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Abstract: 
Background and Aims: The high replication and mutation rate of hepatitis C virus (HCV) results in a 
heterogeneous population of viral sequences in vivo. HCV replicates in the liver and infected hepatocytes 
occur as foci surrounded by uninfected cells that may promote compartmentalization of viral variants. Given 
recent reports showing interferon stimulated gene (ISG) expression in chronic hepatitis C, we hypothesized 
that local interferon responses may limit HCV replication and evolution. Methods: To investigate the spatial 
influence of liver architecture on viral replication we measured HCV RNA and ISG mRNA from each of the 8 
Couinaud segments of the liver from 21 patients undergoing liver transplant.  Results: HCV RNA and ISG mRNA 
levels were comparable across all sites from an individual liver but showed up to 500-fold difference between 
patients. Importantly, there was no association between ISG and HCV RNA expression across all sites in the 
liver or plasma. Deep sequencing of HCV RNA isolated from the 8 hepatic sites from two subjects showed a 
similar distribution of viral quasispecies across the liver and uniform sequence diversity. Single genome 
amplification of HCV E1E2-envelope clones from 6 selected patients at 2 hepatic sites supported these data 
and showed no evidence for HCV compartmentalization. Conclusions: We found no differences between the 
hepatic and plasma viral quasispecies in all patients sampled. We conclude that in end-stage liver disease HCV 
RNA levels and the genetic pool of HCV envelope sequences are indistinguishable between distant sites in the 
liver and plasma, arguing against viral compartmentalization. 
 
Lay Summary: 
HCV is an RNA virus that exists as a quasispecies of closely related genomes that are under continuous 
selection by host innate and adaptive immune responses and antiviral drug therapy.  The primary site of HCV 
replication is the liver and yet our understanding of the spatial distribution of viral variants within the liver is 
limited. High resolution sequencing of HCV and monitoring of innate immune responses at multiple sites 
across the liver identified a uniform pattern of diversity and argues against viral compartmentalization.  
  
Introduction. 
Hepatitis C virus (HCV) is a positive-strand enveloped RNA virus that infects more than 180 million people 
worldwide, with approximately two-thirds of individuals developing a persistent infection. Chronic hepatitis C 
is characterized by a long time course, often extending for decades, that can lead to clinical symptoms 
including fibrosis, cirrhosis and Hepatocellular Carcinoma (HCC). Infection is characterized by ongoing changes 
in viral sequences that enable the virus to persist and evade immune surveillance or anti-viral therapies [1, 2]. 
These “swarms” of related viruses have been detected in the liver and peripheral blood or plasma [3-7].  
The major cell type in the liver that supports HCV infection is the hepatocyte and recent studies suggest that 1 
to 50% of cells are infected and express viral proteins or RNA [8-11]. These infected cells occur as clusters 
surrounded by uninfected hepatocytes, consistent with earlier studies showing HCV dissemination via cell-to-
cell contacts [12, 13]. Such isolated foci of infected hepatocytes support a model of intra-hepatic HCV 
compartmentalization, where viral variants may be localized to discrete regions of the liver. Studies with HIV 
showed evidence for distinct HIV quasispecies in the white pulp areas of the spleen that contribute to the 
reservoir of immune escape variants [14-16]. Our recent study showing that cell-to-cell transmission is the 
most efficient route for HCV to disseminate in vitro [17] supports a model where some viral strains may be 
retained in the liver and not found in the periphery. Collectively, these studies highlight our limited 
understanding of HCV spatial genetic diversity within the liver.  
Chronic hepatitis C is associated with an active interferon (IFN) response showing high levels of IFN-stimulated 
gene (ISG) messenger RNAs in the infected liver [18, 19]. HCV has been reported to disrupt host innate 
immune defenses in vitro [reviewed in [20]], however the significance of these evasion strategies in the 
infected liver are unclear. It is interesting to consider that the clustered pattern of infected cells observed in 
vivo may be explained by local IFN responses limiting viral spread. Indeed, we previously reported that IFNs 
limit the infectivity of secreted HCV particles [21]. Sheahan and colleagues reported increased ISG mRNA in 
‘uninfected’ hepatocytes that were adjacent to HCV infected cells [22], raising questions on the role of this 
activated bystander response in controlling viral replication and in imposing an immune barrier to HCV 
sequence diversity. 
To investigate whether a spatial interplay exists between host innate immune responses, HCV replication and 
genetic compartmentalization we measured ISG levels, HCV RNA and the composition and distribution of viral 
quasispecies in tissue sampled from each of the eight Couinaud segments of the liver and in the plasma of 
patients undergoing liver transplant.  
Materials and Methods 
Clinical samples: Liver tissue and plasma samples were obtained from 21 of 23 patients with chronic HCV 
infection recruited to the ITX5061 in liver transplant recipients trial [23]. All patients gave specific informed 
consent and ethical approval was given by the UK National Research Ethics Service (reference 10/H0301/36). A 
summary of the clinical characteristics and the indications for transplantation, as well as the plasma and 
hepatic viral loads are detailed in Table 1.  Liver tissue from deceased individuals without diagnosed disease 
  
were included as normal controls. These livers had been rejected for liver transplantation due to detectable 
steatosis. On receipt of the explanted liver in the laboratory 250 mg specimens from each of the 8 Couinaud’s 
segments or a single sample from the control livers were collected for RNA extraction as soon as possible after 
explant (Table 1). Briefly, snap frozen samples were added to 4 mL of ice-cold RLT buffer (Qiagen, Germany), 
homogenized using a gentleMACS
TM 
protocol (Miltenyi Biotec, UK), RNA prepared from the homogenate in 
accordance with the manufacturer’s instructions (RNAeasy Midi kit, Qiagen, Germany) and assessed for 
possible degradation (Aligent 2200 Tapestation, all RIN > 7.5). Viral RNA was purified from 5 mL of plasma 
(Viral RNA kit, Qiagen, Germany). Plasma samples used in this study were taken within 12 hours of the start of 
the surgery.  The amount of HCV in the plasma was quantified in International Units (IU)/mL and converted to 
HCV copy numbers using the manufacturer’s guidelines (1 IU = 2.7 HCV copies, Cobas Amplicor 2.0 assay, 
Roche).  
Quantitative Real Time PCR (qRT-PCR): All cellular mRNA levels were quantified using gene-specific primers 
together with a GAPDH endogenous reference gene (TaqMan
®
 Gene Expression Assays, Life Technologies, UK) 
in either an ABI 7500 (96 well) or ABI 7900HT (384 well) PCR machine (Applied Biosciences) using a Cells Direct 
One-Step qRT-PCR kit (Life Technologies, UK). For the detection of HCV a 5’UTR specific primer set was used 
(Primer Design, UK). All measurements were performed in triplicate in two separate qRT-PCR runs. The 
quantity of total RNA recovered from each biopsy sample was determined by spectrophotometry, allowing us 
to adjust the HCV copy numbers according to RNA yield.  
Amplification of HCV structural genes for Single Genome Amplification (SGA): HCV cDNAs for SGA were 
generated using primers specific for either genotype 1a (2616a-1a: GGG ATG CTG CAT TGA GTA, where the 
name reflects the location (H77 numbering), orientation (sense/antisense) and genotype specificity of the 
primer) or genotype 3a (3471a-3a: CAA TAG TTC CAA GAA GGC CCC TAG TTT GCT G). cDNA was generated 
from 5µg RNA using 0.4µM anti-sense primers together with Superscript III Reverse Transcriptase; cDNA 
synthesis was performed for 30 minutes at 55°C, followed by denaturation at 94°C for 2 minutes. Two-step 
“nested” PCR amplifications were set-up on ice using a Phusion™ High-Fidelity DNA polymerase system (New 
England Biolabs, GC buffer) in accordance with the manufacturer’s instructions, with the addition of 4% DMSO 
to improve yield. The first round primers were: genotype 1 (70s: AGA AAG CGT CTA GCC ATG GCG TTA G and 
2616a-1a) or : genotype 3 (70s and 3471a-3a), the PCR amplification conditions were: 30 x (94°C, 15s; 60°C, 
15s; 72°C, 150s). 2 µL of the completed PCR reaction was added to a PCR mixture containing a sense primer 
(166s-CAAC: CAA CGT GGT CTG CGG AAC CGG TGA GTA CAC CG) and either a genotype 1a (2582a-1a:  TTA CGC 
CTC CGC TTG GGA TAT GAG TAA CAT CAT) or genotype 3a (3443a-3a: CCC CTA GTT TGC TGG GCG TAT GCT GTG 
ATC G) antisense primer and re-amplified using the same conditions as in the first PCR. The nested PCR 
reactions were repeated using a Single Genome Amplification (SGA) end-stage limit dilution procedure to 
recover single molecules of HCV, cloned (pcDNA™3.1D/V5-His-TOPO, Life Technologies) and sequenced, as 
previously described [24]. All sequences have been deposited in GenBank under accession numbers KX084541 
- KX084702. 
  
Deep sequencing of HCV structural and non-structural genes: RT-PCR amplification was performed across the 
HCV genome using an overlapping amplicon approach to generate near full-length genomes for deep 
sequencing. For genotype 1a, the first amplicon encompassed the structural proteins from Core to NS2 (H77: 
279-3542), the second spanned from E2 to NS4B (2290-4774) and the third from NS3 to NS5A (4656-7148). A 
fourth amplicon covering the remainder of NS5A and the NS5B region failed to amplify. For genotype 3a, the 
first, second and fourth amplicons were successfully amplified (279-3542 , 2486-5776 and 7373-9365 (NS5A to 
NS5B)) whereas amplicon 3, covering the remainder of NS4B and the 5’half of NS5B, failed amplification.  For 
each amplicon 1-200 ng of hepatic RNA (~ 1,000 HCV copies) or RNA extracted from 100 µL of plasma (~10,000 
HCV copies) was used as input template. For amplicon 1, the reaction consisted of sense (177s: CCT TGT GGT 
ACT GCC TGA TAG) and antisense primers (3542a-1a: GGG YAG CAG TTG ACA CRA TCT or 3542a-3a: CTG GGT 
AGC CGT AGA AAG CAC CT) at 0.4µM, and a Superscript III RT/Platinum Taq Mix in the manufacturers supplied 
First Strand Buffer (Invitrogen), with the following conditions: cDNA synthesis for 30 minutes at 55°C followed 
by heat denaturation at 94°C for 2 minutes, and PCR amplification conditions of 40 x (94°C, 15 s; 58°C, 30 s; 
68°C 240 s), with a final extension at 68°C for 10 minutes. For amplicons 2 and 3 from genotype 1a, this 
reaction consisted of sense (A2F: AAC GTT GCG ATC TGG AAG AC or A3F: GCT CTC ATG ACC GGC TTT AC) and 
antisense primers (A2R: GGA AGC GTG GTT GTC TCA AT or A3R: AGA GAT CTC CCG CTC ATC CT) with the same 
reaction reagents as before but with an adjustment to the PCR amplification conditions, which were 40 x 
(94°C, 15 s; 55°C, 30 s; 68°C 180 s), with a final extension at 68°C for 5 minutes. For amplicons 2 and 4 from 
genotype 3a the primers were : sense (08F: TGG GAT GGG CGY TGA ART GG or 21F: ATG TGT CYG CRG CGC 
TAG C) and antisense (15R: TAG TTT GGT TGG TCG TCA GG or 25R: AGT AGG AGT AGG CAA AGC AGC) at 
0.4µM, with the same reaction reagents as before but with the following reaction conditions; for amplicon 2: 
cDNA synthesis for 30 minutes at 55°C, heat denaturation at 94°C for 2 minutes, then PCR of 40 x (94°C, 15 s; 
55°C, 30 s; 68°C 180 s), with a final extension at 68°C for 10 minutes. For amplicon 4 the PCR conditions were 
40 x (94°C, 15 s; 64°C, 30 s; 68°C 180 s), with a final extension at 68°C for 10 minutes. All PCR products were 
visualized on 1% agarose gels and purified using the PureLink Quick Gel Extraction Kit (Invitrogen).  
For deep sequencing, the PCR amplicons were fragmented and barcoded using NexteraXT DNA Library Prep 
Kit, as per the manufacturer’s protocol.  Samples were pooled and sequenced on an Illumina MiSeq platform, 
using a 2 x 250 bp V2 reagent kit. Paired-end reads were assembled into a HCV consensus sequence using the 
VICUNA de novo assembler software [25] and finished with V-FAT v1.0. Reads were mapped back to the 
consensus using Mosaik v2.1.73, and intra-host variants called by V-Phaser v2.0 [26, 27]. All reads have been 
deposited to the NCBI Sequence Read Archive under the study number SRP065844.  
Assessment of sample diversity: For the deep sequence alignments diversity estimates were calculated as the 
percentage of reads spanning each coordinate that differed from the patient consensus sequence at a 
frequency greater than 1% (referred to as percent codon diversity). For example if 10 of the 27 codons in the 
HVR exceeded this threshold (as seen for patient 1), then the diversity was calculated as 10/27=0.3704 or 
37.04% [28]. SGA derived sequences were aligned, genetic distances estimated and phylogenetic trees built 
using the CLC workbench package (CLC 6.9.1, CLC bio, Denmark) 
  
Statistical analysis: The viral burden and level of host gene expression was calculated for each replicate.  After 
testing for normality (D’Agostino-Pearson test), all of the measurements made were assessed as logarithmic 
transforms. Differences between groups were assessed by Mann-Whitney U test and correlation coefficients 
(r
2
) determined by linear regression. P-values below 0.05 were considered significant. All statistical tests were 
performed using GraphPad Prism 6.0. pSVR calculations were performed in R using the Random Forest method 
as previously described [11, 29].  Statistical estimates of compartmentalization were computed using the 
HyPhy package (http://www.hyphy.org) including; Hudson’s nearest neighbor statistic (Snn), which compares 
the genetic distance between sequences within and between compartments independent of phylogeny 
(Hudson RR, Genetics 155:2011-14), Wright’s measure of population subdivision (FST), and the Slatkin and 
Madison statistic.  
 
Results 
Hepatic Interferon Stimulated Gene expression and HCV Replication. Biopsies were collected from each of the 
eight Couinaud segments of the explanted liver obtained from 21 HCV-infected subjects undergoing liver 
transplantation (Table 1). It is well documented that a pre-existing IFN response de-sensitizes the liver to IFN-
based therapies. Dill and colleagues screened a large panel of ISGs and discovered three genes; ISG15, IFI27 
and RSAD2 (Viperin) that identified patients with elevated endogenous interferon responses [30]. We 
therefore measured ISG15, IFI27, RSAD2 and HTATIP2 mRNA (which acts as an internal referent) levels by qRT-
PCR in all 8 biopsies sampled from the explant liver. We observed comparable levels of ISG mRNA in all 
biopsies sampled from a single liver, with limited variability (ranges: IFI27, 1.2 – 5.7 fold (median 2.1); ISG15, 
0.9 – 2.2 fold (median 1.6); RSAD2, 1.4 – 3.9 fold (median 1.8) (Fig.1A-D). In contrast, we observed large 
differences in ISG mRNA levels between subjects: IFI27: 68-fold, ISG15: 37-fold and RSAD2: 43-fold (one-way 
ANOVA, p < 0.0001). In contrast HTATIP2 mRNA levels only varied 3-fold among biopsies sampled from all 
patients (Fig.1D). Hepatic biopsies from deceased donors with no diagnosed disease were used as ‘normal’ 
controls to measure ISG expression. The majority of HCV infected liver explants (19/21) showed increased 
IFI27 mRNA levels relative to the controls; whereas approximately half showed elevated ISG15 (12/21) or 
RSAD2 (13/21) expression (Fig.1A-D). In contrast only 2 patients showed any elevation of HTATIP2 levels. An 
algorithm to summarize hepatic ISG expression [11, 29, 31] was calculated and 19 of the 21 explants showed 
values below 0.5, consistent with a high level of endogenous ISG expression.  
 
Recent studies show the major interferon (IFN) induced by HCV infected hepatocytes is type III IFNλ [32, 33]. 
Amplification of IFNλ mRNA gave very low signals, with many biopsies producing no PCR product (no 
amplification in 35 cycles). In those cases where IFNλ mRNA was detectable, the levels were much lower 
(5,000 – 20,000 fold) than the IFI27, ISG15 and RSAD2 mRNAs, and similar levels were detected in all 8 biopsies 
(<10 fold variation) suggesting that, when present, IFNλ is uniformly expressed across the liver (data not 
shown). Together these data show a remarkably uniform distribution of ISGs in biopsies sampled across 
multiple segments of the liver, however, we noted a wide range of ISG expression between subjects. 
  
 
In parallel with monitoring ISG mRNA levels in the liver biopsies we measured HCV RNA. The viral RNA burden 
in the 8 biopsies from a single explant varied from 1.47 to 6.17 fold (median 3.19), with 7 of the 21 livers 
showing higher than 5 fold variation across all sites sampled (Fig.2A). In contrast, the viral RNA burden varied 
by over 500-fold between patients, from 1.4 (± 0.6) to 228 (± 48.1) HCV copies/ng RNA. HCV RNA levels were 
independent of the infecting viral genotype or clinical diagnosis (Table 1). We saw no evidence for any 
association between intra-patient variance and HCV RNA burden (r
2
 = 0.07, n.s., Fig.2C). The levels of HCV RNA 
detected in the plasma at the time of the transplant varied by over 10,000 fold between patients, ranging from 
8.2 x 10
2 
to 3.7 x 10
7
 genomes/mL (Fig.2B). These large variations in plasma and liver HCV RNA led us to assess 
the correlation between the viral burden in the two compartments. A low but significant correlation was 
observed (r
2
 = 0.13, p < 0.0001), suggesting that plasma load is a relatively poor predictor of hepatic burden 
(Fig.2D).  
 
There was no correlation between the intra-hepatic ISG mRNA and HCV RNA in the same biopsy or plasma 
load (IFI27: Pearson’s r
2
 = 0.007 (p = 0.72), ISG15: r
2
 = 0.016 (p = 0.59), RSAD2: r
2
 = 0.007 (p = 0.73). A 
combined multivariate analysis of ISG mRNA levels against viral burden was similarly non-significant (r
2
 = 0.039, 
F-ratio = 0.25, p = 0.86). In summary, we found no evidence for hot spots of viral replication, with comparable 
HCV RNA loads detected across all segments in twenty one subjects that was independent of ISG expression.  
 
Hepatic HCV quasispecies. Recent advances with deep sequencing technologies have made it possible to 
investigate the viral quasispecies in unprecedented detail, allowing us to perform a comprehensive assessment 
of the distribution and evolution of viral sequences across the liver. From our earlier studies measuring hepatic 
ISG and HCV RNA levels, we selected patients 1 (genotype 3) and 2 (genotype 1a) as representative cases of 
the two major infecting genotypes in our cohort. The genomes were sequenced for patient 1 (H77 position 279 
– 5776 and 7373 - 9365) and patient 2 (279 – 7148) using deep sequencing (Illumina MiSeq). The mean 
sequence coverage at each nucleotide position was 5894 ± 1511 (patient 1) and 7465 ± 2399 (patient 2), 
allowing us to detect variants in the viral population at a frequency of < 0.1% [26].  
 
The genetic diversity among all hepatic sites in both patients revealed a striking similarity across the structural 
and non-structural regions. That is, not only were the same codons variable, the total diversity was similar in 
all samples (Fig.3 and Table 3). For instance within patient 1, there were two residues (L144 and V162; H77 
numbering) within the Core protein that were polymorphic throughout all samples. The first position was 
highly diverse with alanine to valine substitutions occurring at frequencies of 35% (segment 8) to 43% 
(segment 4) (Fig.3A and Table 3A). At the second site an isoleucine to valine polymorphism was observed, 
ranging in frequency from 18% (segment 8) to 25% (segment 3). Although a few sites differed between hepatic 
segments generally all of these sites were low frequency variants at below 5%. Similar data were obtained for 
patient 2, with the same polymorphisms found across all 8 hepatic segments (Fig.3B and Table 3B) and only 
subtle differences observed with low frequency variants. However, one unique polymorphism (A573, NS3) was 
  
found to be restricted to a single hepatic segment (segment 5) at a frequency >10% (Fig.3B). As expected the 
majority of polymorphic sites were located in the first hypervariable region of E2 (HVR1) (Fig.3 and Table 3). In 
patient 1, we noted that the level of diversity in the HVR region was 5 times higher than in the rest of E2, while 
in patient 2 this diversity was 6 times greater. Although unique low frequency variants were detected in the 
liver samples, no specific variants were enriched in any particular sample and there was no evidence for 
signature sequences associated with a hepatic location (Fig.3 and Table 3).  
 
To further investigate the HCV quasispecies a subset of 6 patients (3 genotype 1a, 3 genotype 3) was selected 
for single genome amplification (SGA) by limit dilution PCR. The same hepatic RNA employed for deep 
sequencing was used as the template for a nested PCR and SGA. A total of 118 SGA-derived HCV E1E2 clones 
were obtained and sequenced, with an average of 20 clones per patient. Surprisingly we found no evidence for 
elevated polymorphism in the regions of the genotype 3a E2 region previously identified as HVR2 and HVR3 
[34, 35], or in HVR495 and HVR575 [36].  
 
The SGA clones allowed us to assess selection pressures by comparing the rate of substitutions at non-
synonymous sites (dN) to the rate of substitutions at synonymous sites (dS) across the E1E2 region. The 
majority of substitutions were synonymous, with observed dN/dS ratios between 0.07 and 0.65 (Table 2). As 
expected, the majority of dN changes localised to the HVR1, leading to the highest dN/dS ratios in this region 
(Table 2). Elevated frequencies of dN genetic changes have previously been associated with the innate and 
adaptive immune response [37]. We saw no correlation between ISG mRNA levels and the dN/dS ratio for 
E1E2 or HVR1 (E1E2 r
2
 = 0.33 ± 0.027 p = 0.59, HVR1 r
2
 = 0.05 ± 0.023 p = 0.25).  Taken together, deep 
sequencing and SGA show similar patterns of viral genetic variation across the liver that are independent of 
ISG expression during end-stage liver disease (ESLD).  
 
Plasma HCV quasispecies. Given the relatively poor correlation between hepatic and plasma HCV RNA levels, 
we were interested to determine whether all members of the hepatic quasispecies were represented in the 
plasma. Deep sequencing of plasma HCV RNA from patients 1 and 2 showed a similar pattern of diversity to 
the hepatic segments (Fig.3 and Table 3). For example, the two variable residues (Core L144 and V162) noted 
in the liver segments from patient 1 were present in the plasma at similar frequencies (L144: 43% vs. 40% ± 
2.7; V162: 20% vs. 22% ± 2.2). Overall, the levels of codon diversity in plasma viral RNA were similar to those 
measured in the liver (Core: 2.62% and 2.55% ± 0.19; E1: 5.73% and 5.14% ± 0.86; E2: 6.23% and 5.86% ± 0.20; 
p7: 14.28% and 11.11% ± 1.90; NS2: 4.15% and 4.09% ± 0.83; NS3: 3.01% and 3.70% ± 0.86; NS4A: 0% and 
2.32% ± 1.64; NS4B: 2.30% and 1.44% ± 1.34; NS5A: 2.44% and 3.05% ± 3.63; NS5B: 0.87% and 1.82 % ± 1.19, 
respectively). Within NS5B, two Threonine codons (T66 and T340) differed between the plasma and the 
hepatic segments. At position 66 the plasma harbours a dominant alanine codon at this position (61%) with 
threonine as the minor variant (39%). In contrast the hepatic segments contain a threonine codon (95%-99%) 
with the alanine only rarely seen, at a maximum frequency of 3.8%. Similarly, at position 340 in the plasma, in 
addition to the dominant threonine codon, a methionine variant was observed at a frequency of 33%. This 
  
variant was only seen in 6 of 8 hepatic segments and at a maximum frequency of 2%.   For patient 2 
concordant patterns of diversity were observed in the plasma and hepatic segments, with similar levels of 
codon diversity in plasma and liver samples (Core: 1.05% and 0.72% ± 0.39; E1: 1.56% and 2.02% ± 0.18; E2: 
9.09% and 8.81% ± 0.66; p7: 3.17% and 4.37% ± 1.12; NS2: 7.37% and 6.86% ± 1.51; NS3: 11.09% and 10.76% ± 
1.32; NS4A: 3.70% and 1.85% ± 0; NS4B: 14.94% and 15.33% ± 2.61; NS5A: 6.29% and 3.98% ± 0.97, 
respectively). In this patient one mutation within NS3 (T563) was not detected in plasma but was found in 
hepatic segments 1,7 and 8 at a frequency of 11-13% (Fig.3B).  
  
Within the HVR1 we found an average of 9.7 (± 0.9) amino acid polymorphisms for patient 1 and 14.7 (± 0.7) 
for patient 2 (considering only those sites with >1% prevalence) (Fig.3A and Table 3A). The heat maps reflect a 
diverse quasispecies within the plasma from patient 1, with numerous polymorphisms within HVR1 (Fig.3 and 
Table 3). The two viral variants present at greater than 10% frequency were also most prevalent in the liver 
(Fig.3 and Table 3). All plasma variants were observed in the hepatic samples, including minority variants. A 
more homogeneous population was observed in patient 2, with only one major variant present, constituting 
73.4% of the plasma sequences and ranging in abundance from 66.3% to 73.5% in the liver. Several minor 
variants (<5%) were distributed throughout all sites sampled with all variants shared with the plasma at some 
frequency (Fig.3B and Table 3B).  
 
The Shannon entropy algorithm can be used to quantify the relative frequency of the variants within a sample. 
We obtained values of 0.028 (plasma) and 0.021 ± 0.007 (hepatic) for patient 1. Similar values were calculated 
for patient 2 of 0.017 (plasma) and 0.032 ± 0.005 (hepatic) (Table 2), demonstrating similar levels of 
polymorphism at all sites. Quantifying the selection pressures acting on each sample revealed a high 
proportion of synonymous substitutions across both structural and non-structural regions and elevated rates 
of dN changes within the HVR. This pattern was independent of the site of origin, indicating that both plasma 
and hepatic quasispecies were evolving in a similar fashion (data not shown). These observations confirm 
those obtained by SGA sequencing and show concordant results independent of sequencing technology. The 
high dN substitution rate implies that, even in end-stage liver disease, some viral variants may be the result of 
selective host immune pressure.  
 
Phylogenetic analysis of HCV compartmentalization. Our complete data set of HCV sequences from the liver 
and plasma allows us to rigorously assess genetic compartmentalization. A phylogenetic comparison by the 
Neighbour Joining method of consensus or SGA-derived nucleotide sequences showed no evidence for biopsy-
specific sequences (Fig.4A). Although the sequences obtained from the livers of patients 2, 4 and 5 showed a 
few pairings, where two SGA sequences from the same hepatic segment grouped together, these clusters 
included sequences isolated from other sites within the liver. SGA sequences from different liver biopsies were 
dispersed across their phylogenetic trees, with no site-specific clustering. In patient 7 there was weak evidence 
for some clustering, with SGA sequences from segments 1 and 6 grouping together and two SGA sequences 
from segment 1 grouping with their cognate consensus sequence. This was supported statistically by the tree-
  
based Slatkin-Maddison (SM) test (p = 0.02, inferred migration events: 2). There was no evidence of population 
structure for the other five patients (mean p = 0.67, ± 0.38, mean inferred migration events: 2.72, ± 1.49) 
(Table 2). When we repeated this analysis using the deep sequencing data from patients 1 and 2, we found no 
evidence for intra-hepatic compartmentalization (p > 0.05). 
 
Analysis of sequences from patient plasma showed limited evidence of compartmentalization, with similar 
genetic distances among the plasma- and liver-derived sequences making it impossible to map the source of 
the plasma sequences to any specific location in the liver (Table 2 and Fig.4B). Examination of the liver as a 
single entity also showed no evidence for HCV compartmentalization between plasma using either the SM test 
(Patient 1, p = 1; Patient 2, p = 1) or two other alternative methods for assessing population structure; Wright’s 
measure of population subdivision (Fst) and Hudson’s Nearest Neighbor statistic (Snn), (Patient 1, Fst  p = 0.74, 
Snn p = 0.79; Patient 2, Fst p = 0.96, Snn p = 0.42). Overall these data confirm the observations made using the 
SGA sequences and show that even deep sequencing of the plasma and liver segments failed to detect any 
major differences between the viral quasispecies at different sites. Furthermore, the simultaneous presence of 
identical HCV quasispecies variants in the different segments of the liver supports our conclusion that intra-
hepatic compartmentalization is not a hallmark of end stage liver disease.  
 
 
Discussion 
The goal of this study was to assess the spatial relationship between innate immune responses, HCV RNA 
burden and viral quasispecies diversity across the eight Couinaud segments of the liver from patients 
undergoing liver transplant. This collection of clinical material provides a novel insight into the relationship 
between hepatic ISG expression and the viral quasispecies in the liver and periphery. 
We used the 4-gene IFN classifier developed by Dill and colleagues [30] to assess ISG expression in the 
explanted liver and found a remarkably consistent level of expression, regardless of the site of sampling. In 
contrast, we observed variable hepatic ISG response between patients, irrespective of their diagnosis of 
cirrhosis or HCC. Importantly, the ISG response across the liver showed no correlation with HCV RNA burden in 
subjects with ESLD. Using needle biopsies collected in earlier stages of disease, other groups have also failed to 
observe an association between hepatic ISG expression and HCV RNA levels [9, 30, 38, 39]. We conclude that 
in chronic late stage hepatitis C innate interferon signaling has limited impact on HCV replication or HCV 
genetic diversity. 
The levels of HCV RNA in all eight biopsies sampled from a single liver were surprisingly similar, suggesting that 
the liver is uniformly infected during end-stage liver disease. Previous studies have shown comparable levels of 
HCV RNA in biopsies sampled from up to three different regions of a liver [40-43]. Several studies have 
suggested that the frequency of HCV infected hepatocytes in the liver is low, ranging from 5% to 20% [8, 9, 11, 
39], supporting a model of genetic compartmentalization. Wieland and colleagues have suggested that 
infected foci comprising < 5% of hepatocytes in the liver occur when the plasma HCV RNA burden is <10
5
 
  
copies/mL and that above this threshold the frequency of infected hepatocytes can range from 20 – 50%. In 
our cohort 18 of the 21 patients showed plasma HCV RNA levels well above this threshold (Fig.2), suggesting 
that ‘local’ compartmentalization within a segment may be lost in late stage disease when the frequency of 
infected cells is high. In contrast to the limited intra-hepatic variation in HCV RNA levels we noted significant 
differences between patients of up to 500-fold [11, 39]. These differences were unrelated to the patient’s age, 
indication for transplantation, or infecting HCV genotype (Table 1). Although it is possible that patients with 
high hepatic viral loads will have more HCV infected cells or higher amounts of HCV RNA per infected cell, the 
complex microscopic approaches to visualize these cells using HCV core or NS5A antibodies or patient-specific 
viral nucleic acids were beyond the scope of this study [8, 11]. 
One could predict that the diversity of HCV quasispecies would decrease in late stage disease due to a reduced 
immune response, while the more active immune responses in the earlier phases of infection may select for a 
greater diversity of HCV quasispecies [44, 45]. HCV sequence variation was readily detectable, though it is not 
possible to distinguish whether this is in response to ongoing selection or a relic of earlier evolutionary factors. 
We assessed genetic polymorphism using both single gene amplification and deep sequencing approaches. 
Although SGA cloning and sequencing methods offer the advantage of identifying whole regions of the virus, it 
is costly and the number of clones that can be obtained is limited [46-49]. Deep sequencing approaches 
overcome the relatively poor sampling inherent in SGA by analyzing thousands of short viral gene fragments. 
This allows us to base our calculations on many hundreds of sequences and derive our diversity estimates with 
complete precision. In this study, the average number of reads for each base of the E1E2 region was 3,045-
11,824, which is much larger than previous studies often with <20 sequences reported [46-49]. Interestingly 
we were able to demonstrate that, even with the limited sampling inherent in the method, our SGA-based 
inferences of genetic diversity closely reflected those obtained from deep sequencing. Furthermore, the 
sequences of our SGA clones were the most abundant members of the quasispecies identified by deep 
sequencing (Table 2), demonstrating that SGA recovers the most representative sequences in the population.   
 
Comparing liver-derived HCV quasispecies with plasma showed a high degree of overlap, though the relative 
abundance of the variants differed between the two compartments and a few unique sequences were 
observed in each sample (Table 3). These differences may reflect the hepatic retention of poorly released (cell-
to-cell transmitted) HCV variants [13]. Alternatively neutralizing antibodies may mediate the clearance of some 
viruses, leading to an over representation of neutralization escape mutants in the periphery [3, 50, 51]. Extra-
hepatic viral reservoirs are another potential source of viruses in the plasma that were not detected in the 
liver, a model supported by the detection of HCV negative strand RNA in PBMCs [52, 53], lymph nodes [54] and 
the central nervous system [55]. These extra-hepatic sites have been suggested to serve as reservoirs for 
viruses to re-infect the allograft after transplantation [56-61].  
To the best of our knowledge these data represent the most comprehensive study on intra-hepatic HCV 
compartmentalization to date using both structural and non-structural proteins. It reveals high levels of 
sequence similarities between different sites in the liver, supported by all HVR1 sequences being present in at 
  
least 2 hepatic segments and by sub-populations of dominant sequences being identical across segments. 
Several studies have compared HCV sequences in the liver and plasma. Some report a genetic relationship 
between viral strains present in both compartments [3, 42] with half of the patients sharing the same 
consensus sequence in plasma and liver, together with a unique site-specific set of minor sequences [3, 42, 
50]. In contrast, Fan and colleagues found no evidence for association between these sites [51]. These high 
genetic similarities between the hepatic segments may reflect a long history of chronic infection where 
genetically distinct clusters have been lost over time. 
Sobesky and colleagues [62] reported HCV compartmentalization between tumor and non-tumor regions of 
the liver in 5 of 7 patients diagnosed with hepatocellular carcinoma (HCC). Consistent with these findings a 
recent study by Harouaka et al. reported differences in HCV quasispecies distribution between tumor and non-
tumor compartments [63], supporting a model where HCV may evolve differently in non-tumor cirrhotic 
nodules. However, both of these studies assessed genetic compartmentalization using the matrix-based 
Mantel’s test of genetic and anatomical distances that has been criticized for its statistical performance [64, 
65]. We therefore used the more rigorous Slatkin-Maddison test to evaluate compartmentalization, which 
infers the number of migration events between compartments using the structure of the reconstructed 
phylogenetic tree. While two subjects (patients 4 and 7) were diagnosed with HCC, no evidence for E1E2 
compartmentalization was obtained. HCC was not detected in all 8 segments of these livers, therefore our 
comparisons focused on non HCC biopsies. Many reports of HCV quasispecies genesis are based on a demic 
model of viral evolution where isolated variants arise in geographically distinct locations. However, our data 
on HCV quasispecies in the explanted liver and plasma suggest that in late stage liver disease HCV 
compartmentalization does not occur. 
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Figure Legends: 
 
Fig.1: Interferon Stimulated Gene expression in the HCV infected liver. RNA was extracted from biopsies 
sampled from the 8 segments of the explanted liver of patients diagnosed with chronic hepatitis C (Genotype 1 
[Gt1] n=13; Genotype 3 [Gt3] n=7 and Genotype 2 [Gt2] n=1) and from a single biopsy collected from 6 normal 
controls. The mRNA levels for ISG15 (A), IFI27 (B), RSAD2 (C) and HTATIP2 (D) were quantified and normalized 
with an internal GAPDH mRNA expression referent. Data are presented for each biopsy sample showing the 
mean expression levels ± SD (blue horizontal bar) and the average values for the total liver denoted in the 
right-hand panel along with controls (red). The dashed horizontal line denotes the mean expression of normal 
biopsies. 
 
Fig.2: HCV RNA levels in the liver and plasma at the time of transplant. The levels of HCV RNA in the hepatic 
RNA (A) samples described in Fig.1 along with the plasma-derived RNA (B) were quantified by RT-PCR. Data are 
presented for each biopsy showing the mean expression HCV RNA/ng total RNA (open circles) and from 
matched plasma samples showing HCV RNA/mL plasma (closed circles). The mean HCV RNA level ± SD is 
indicated for each liver. To assess whether the hepatic viral RNA burden (mean HCV RNA of all 8 liver samples) 
dictates variation across the liver (coefficient of variance - HCV RNA variance/mean HCV RNA) (C) or plasma 
RNA levels (D) we measured the correlation between these parameters. 
 
Fig.3. Deep sequencing of HCV hepatic and plasma quasispecies. Linear heat map representation of amino 
acid diversity within the structural and non-structural proteins for the plasma and for the 8 segment biopsies 
from Patient 1 (A) and Patient 2 (B). Each square represents a polymorphic codon, coloured to reflect the 
percentage of reads that exhibit diversity. The diversity scale is colour coded with highly conserved residues in 
black. Low frequency polymorphisms (<10%) are in dark blue, intermediate levels of polymorphism shade from 
blue (10%) to green (45%), with the most highly variant residues (45% - 60%) shaded from green to orange. 
Only codons exhibiting diversity greater than 1% are shown.           
 
Fig.4: Phylogenetic relationships between HCV sequences in liver and plasma. The relationships between 
HCV E1E2 SGA sequences derived from selected hepatic segments and plasma were assessed by Neighbour 
Joining analysis. There was minimal evidence for clustering of SGA-derived sequences originating from the 
same hepatic segment. The upper phylogenetic trees denote sequences from patients 1, 4 and 5 (Genotype 3) 
while the lower trees represent patients 2, 7 and 9 (genotype 1a). In each tree black squares denote SGA-
plasma sequences, whereas colored circles denote SGA-hepatic sequences derived from segment 1 (green), 3 
(cyan), 6 (blue) or 7 (grey). Red triangles represent consensus nucleotide sequences obtained from each of the 
eight hepatic segments (A). Quantification of mean genetic distance between SGA-derived sequences from 
identical or different hepatic sites and plasma (B). 
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Table	1	:	Individual	Patient	details	
	
                        
    Genotype	1  		 Genotype	3 G	2	 	
             		 	        		 	
 Patient	no
1.	 2	 3	 6	 7	 9	 13	 15	 16	 19	 20	 21	 22	 1	 4	 5	 8	 14	 17	 18	 23	 11	 Medians	
	
Age	
(Years)	 39	 62	 56	 58	 58	 49	 39	 38	 47	 49	 54	 64	 58	 57	 48	 35	 58	 58	 62	 62	 62	 57	
	 Gender	 Male	 Male	 Female	 Male	 Male	 Male	 Male	 Male	 Male	 Male	 Male	 Male	 Male	 Male	 Male	 Female	 Male	 Male	 Male	 Male	 Male	 		
	
Bilirubin	
(µmol/L)	
52	 16	 24	 23	 75	 56	 71	 83	 43	 51	 48	 58	 33	 30	 55	 21	 14	 53	 26	 21	 12	 46	
	
Creatine	
(µmol/L)	 68	 93	 79	 64	 86	 108	 60	 112	 60	 84	 97	 66	 90	 138	 117	 49	 79	 108	 46	 59	 83	 82	
	 INR	 1.8	 1.2	 1.3	 1.6	 1.9	 1.5	 1.8	 1.6	 1.3	 1.5	 1.3	 1.6	 1.2	 1.7	 1.6	 2	 1.3	 1.4	 1.3	 1.3	 1	 1.5	
	 MELD	 17	 9	 11	 13	 19	 17	 18	 20	 13	 15	 14	 16	 11	 19	 19	 15	 10	 16	 11	 11	 7	 15	
	 Indication	
Liver	
failure	 HCC	
Liver	
failure	 HCC	
Liver	
failure	
Liver	
failure	
Liver	
failure	
Liver	
failure	
Liver	
failure	
Liver	
failure	
Liver	
failure	
Liver	
failure	
Liver	
failure	 HCC	
Liver	
failure	
Liver	
failure	 HCC	
Liver	
failure	
Liver	
failur
e	
Liver	
failure	 HCC	 		
	
HCV	
genotype	 1a	 1b	 1	 1a	 1	 1	 1	 1	 1	 1a	 1b	 1a	 3	 3a	 3a	 3a	 3	 3	 3	 3a	 2	 		
	
Plasma	
viral	load	
(copies/mL)	
1,996,372	 1,634,072	 2,901,274	 521,278	 132,972	 351,000	 83,700	 3,240	 32,400,000	 2,970,000	 8,100,000	 1,053,000	 1,319,636	 280,271	 824	 133,078	 118,800	 810,000	 207,900	 3,240,000	 5,431,116	 665,639	
	
Mean	
hepatic	
viral	load	
(copies/ng	
total	RNA)	
169	 152	 753	 74	 55	 49	 235	 39	 401	 66	 742	 117	 28	 14	 124	 12	 1.42	 31	 122	 33	 823	 70	
	
Liver	
processing	
time	
(hours)	
13.8	 2.5	 16	 7.5	 15.3	 22.5	 5	 2.3	 6	 3.25	 13.2	 21	 16	 20.25	 4	 6.7	 12	 6	 5.5	 6.7	 3.5	 7	
	
1) 2	patients	were	excluded:	the	liver	from	patient	10	was	damaged	by	hydatid	disease	(echinococcosis),	patient	12	did	not	consent	to	sampling.	
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28 
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31 
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Table	2:	HCV	Sequence	information	
	
Patient	
No.	
Genotype	 Diagnosis	 Number	of	
SGA	
sequences	
Number	of	detected	
polymorphisms	
Mean	Shannon	
entropy/nucleotide	
Slatkin-	Maddison	 dN/dS4	
p-value	(inferred	
migration	events)3	
Liver	 Plasma	 Consensus1	
SGA	
(Liver	+	
Plasma)2	
Liver	 Plasma	 Liver	+	Plasma	 Liver	
Liver	vs.	
plasma	
Liver	
E1E2	
Plasma	
E1E2	
Liver	
HVR1	
Plasma	
HVR1	
1	 	 C	 8	 9	 21.7	(9.7)	 160	 0.021	 0.028	 0.028	
0.44	
(1.5)	
0.33	
(2.5)	 0.14	 0.17	 1.55	 1.38	
4	 3a	 HCC	 11	 7	 34.1	(1.7)	 100	 0.018	 0.018	 0.020	
0.34	
(3)	
1	
(7)	 0.65	 0.49	 3.25	 2.49	
55	 	 C	 20	 -	 42.7	(12.4)	 199	 0.035	 -	 -	
0.76	
(3.25)	 -	 0.17	 -	 0.56	 -	
2	 	 C	 15	 7	 65.3	(11.3)	 204	 0.032	 0.017	 0.031	
0.25	
(3)	
1	
(7)	 0.14	 0.10	 2.06	 ∞6	
7	 1a	 HCC	 14	 11	 38.4	(11.9)	 209	 0.030	 0.023	 0.031	
0.02	
(2)	
0.22	
(7)	 0.15	 0.21	 0.16	 0.30	
9	 	 C	 10	 7	 46.7	(3.1)	 125	 0.029	 0.031	 0.032	
0.88	
(4)	 1	(7)	 0.07	 0.08	 0.99	 1.21	
	
1	Mean	number	of	polymorphisms	per	consensus	sequence	(Standard	Deviation)	
2	Total	number	of	polymorphic	sites	within	the	sequence	alignment.		
3	Mean	p-value	and	inferred	migration	events	between	liver	biopsies	and	between	liver	and	plasma.		
4	dN/dS-ratio	were	calculated	from	the	average	dN	and	dS	of	all	pairwise	comparisons	between	sequences.	
5	Patient	5	did	not	have	any	amplifiable	HCV	in	the	plasma.		
6	No	synonymous	changes	were	detected	among	the	plasma	derived	HVR1	sequences	in	Patient	2.	The	dN	value	for	this	patient	was	0.05.				
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Table 3: HVR polymorphism 
 
A: Patient 1 HVR1 polymorphisms detected by Deep Sequencing 
HVR1  Plasma Seg1 Seg2 Seg3 Seg4 Seg5 Seg6 Seg7 Seg8 
HTYTTGSSPARGASMIASMFAPGARQN 27.3%
1 
(42) 
32.9% 
(25) 
28.4% 
(61) 
26.9% 
(46) 
38.0% 
(76) 
41.2% 
(61) 
31.7% 
(91) 
44.3% 
(100) 
42.9% 
(66) 
..H....IAG....R...I........ 20.8% 
(32) 
10.5% 
(8) 
14.4% 
(31) 
13.5% 
(23) 
9.0% 
(18) 
18.9% 
(28) 
15.0% 
(43) 
11.1% 
(25) 
3.9% 
(6) 
Q.H....IA.....T...I........ 11.7% 
(18) 
14.5% 
(11) 
9.3% 
(20) 
8.2% 
(14) 
10.0% 
(20) 
16.9% 
(25) 
14.3% 
(41) 
8.4% 
(19) 
9.7% 
(15) 
..................I........ 11.0% 
(17) 
10.5% 
(8) 
5.6% 
(12) 
10.5% 
(18) 
8.5% 
(17) 
3.4% 
(5) 
9.0% 
(23) 
11.1% 
(25) 
15.6% 
(24) 
.................NI........ 6.5% 
(10) 
10.5% 
(8) 
10.2% 
(22) 
9.9% 
(17) 
9.5% 
(19) 
4.7% 
(7) 
67.0% 
(20) 
5.8% 
(13) 
7.8% 
(12) 
.................NI.S...... 
5.2% 
(8) 
7.9% 
(6) 
7.0% 
(15) 
10.0% 
(17) 
7.5% 
(15) 
0% 
(0) 
3.5% 
(10) 
4.9% 
(11) 
0% 
(0) 
.................GI........ 
5.2% 
(8) 
7.9% 
(6) 
5.1% 
(11) 
4.1% 
(7) 
0% 
(0) 
0% 
(0) 
4.9% 
(14) 
3.5% 
(8) 
5.2% 
(8) 
Q.H....IA....NS...I........ 
2.6% 
(4) 
2.6% 
(2) 
3.3% 
(7) 
2.3% 
(4) 
2.0% 
(4) 
4.7% 
(7) 
1.1% 
(3) 
3.1% 
(7) 
1.3% 
(2) 
..............G...I........ 
2.0% 
(3) 
0% 
(0) 
3.3% 
(7) 
0% 
(0) 
2.0% 
(4) 
2.7% 
(4) 
2.1% 
(6) 
2.2% 
(5) 
1.3% 
(2) 
.............N....I........ 
1.3% 
(2) 
0% 
(0) 
2.8% 
(6) 
3.5% 
(6) 
4.5% 
(9) 
1.4% 
(2) 
3.5% 
(10) 
0% 
(0) 
3.3% 
(5) 
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....................S...... 
1.3% 
(2) 
0% 
(0) 
1.9% 
(4) 
3.5% 
(6) 
2.0% 
(4) 
0% 
(0) 
1.7% 
(5) 
3.1% 
(7) 
2.0% 
(3) 
Q.H....IA....HS...I........ 
0% 
(0) 
0% 
(0) 
1.9% 
(4) 
1.8% 
(3) 
3.0% 
(6) 
4.7% 
(6) 
2.4% 
(7) 
0% 
(0) 
2.6% 
(4) 
Total2  94.8% 
(104) 
97.4% 
(68) 
93.0% 
(139) 
67.3% 
(161) 
96.0% 
(192) 
98.4% 
(145) 
96.1% 
(232) 
97.4% 
(220) 
95.5% 
(148) 
 
 
1) Frequency of sequence (number of reads in brackets) 
2) The difference between the column total and 100% reflects the presence of sequences at a 
frequency of < 1%, 1,409 of the 1,538 HVR1 sequences (91.6%) detected in this patient are 
shown here. 
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B: Patient 2 HVR1 polymorphisms detected by Deep Sequencing 
HVR1  Plasma Seg1 Seg2 Seg3 Seg4 Seg5 Seg6 Seg7 Seg8 
NTHVTFFSAARDVLGFRNFFTLGPRQN 88.5%
1 
(437) 
90.9% 
(331) 
85.5% 
(364) 
78.6%  
(331) 
81.8% 
(437) 
82.9% 
(334) 
87.3% 
(434) 
85.4% 
(729) 
83.6% 
(583) 
Q.........HTAW.LTSLLAP.AK.. 
0.8%  
(4) 
3.3% 
(12) 
2.4% 
(10) 
5.5% 
(23) 
3.4% 
(18) 
4.0% 
(12) 
2.4% 
(12) 
2.7% 
(23) 
5.2% 
(36) 
..................L.....K.. 
4.9% 
(24) 
1.4% 
(5) 
3.1% 
913) 
3.8% 
(16) 
1.7% 
(9)  
4.0% 
(16) 
2.4% 
(12) 
1.6% 
(14) 
4.2% 
(29) 
.................D......K.. 
3.3% 
(16) 
1.1% 
(4) 
1.2% 
(5) 
2.9% 
(12) 
1.1% 
(6) 
3.0% 
(12) 
0% 
(0) 
1.3% 
(11) 
0.3% 
(2) 
.............S..AK..IR..S.. 
0% 
(0) 
0% 
(0) 
0% 
(0) 
2.1% 
(9) 
0.4% 
(2) 
0.7% 
(3) 
0.4% 
(2) 
0.7% 
(6) 
0.9% 
(6) 
S.......................... 
0% 
(0)  
0% 
(0) 
0% 
(0) 
0% 
(0) 
2.8% 
(15) 
0% 
(0) 
1.2% 
(6) 
0% 
(0) 
0% 
(0) 
Total2 97.5% 
(481) 
96.7% 
(352) 
92.2% 
(392) 
92.9% 
(391) 
91.2% 
(487) 
94.6% 
(377) 
93.7% 
(466) 
91.8% 
(783) 
94.2% 
(656) 
 
 
1) Frequency of sequence (number of reads in brackets) 
2) The difference between the column total and 100% reflects the presence of sequences at a 
frequency of < 1%, 4,385 of the 4,683 HVR1 sequences (93.6%) detected in this patient are 
shown here. 
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